These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31281864)

  • 1. Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible
    Beganovic M; Cusumano JA; Lopes V; LaPlante KL; Caffrey AR
    Open Forum Infect Dis; 2019 Jul; 6(7):ofz270. PubMed ID: 31281864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
    McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
    Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
    Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
    BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
    Hamad Y; Nickel KB; Olsen MA; George IA
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
    Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Bigseth RS; Sandholdt H; Petersen A; Østergaard C; Benfield T; Thorlacius-Ussing L
    Microbiol Spectr; 2022 Jun; 10(3):e0153021. PubMed ID: 35438533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
    Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
    Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
    J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Hess KA; Kooda K; Shulha JA; Mara K; Go JR; Fida M; DeSimone DC; Stevens RW
    J Clin Microbiol; 2023 Apr; 61(4):e0003923. PubMed ID: 36988505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
    J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
    Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
    Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
    Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
    Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
    Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
    Flynt LK; Kenney RM; Zervos MJ; Davis SL
    Infect Dis Ther; 2017 Jun; 6(2):225-231. PubMed ID: 28265972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
    Youngster I; Shenoy ES; Hooper DC; Nelson SB
    Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
    Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Mossman AK; Svishchuk J; Waddell BJM; Izydorczyk CS; Buckley PT; Hilliard JJ; Al-Ghalith G; Zheng L; Lynch AS; Mody CH; Lisboa LF; Gregson DB; Parkins MD
    Ann Am Thorac Soc; 2022 Aug; 19(8):1285-1293. PubMed ID: 35213810
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidemiology and impact of methicillin-sensitive
    Svishchuk J; Ebbert K; Waddell B; Izydorczyk C; Acosta N; Somayaji R; Rabin HR; Bjornson CL; Lisboa L; Gregson DB; Conly JM; Surette MG; Parkins MD
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0013623. PubMed ID: 37966229
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study.
    Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM
    BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.